Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Dow
AstraZeneca
Baxter
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,919,115

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,919,115
Title:Orally disintegrating tablet compositions of lamotrigine
Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
Inventor(s): Venkatesh; Gopi M. (Vandalia, OH), Vyas; Nehal H. (Huber Heights, OH), Gosselin; Michael (Loveland, OH), Lai; Jin-Wang (Springboro, OH)
Assignee: Eurand, Inc. (Valdalia, OH)
Application Number:12/166,757
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,919,115
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 7,919,115

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline Llc LAMICTAL ODT lamotrigine TABLET, ORALLY DISINTEGRATING;ORAL 022251-001 May 8, 2009 AB RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Glaxosmithkline Llc LAMICTAL ODT lamotrigine TABLET, ORALLY DISINTEGRATING;ORAL 022251-004 May 8, 2009 AB RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,919,115

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 068185   Start Trial
Australia 2008272871   Start Trial
Brazil PI0814408   Start Trial
Canada 2693072   Start Trial
China 101801192   Start Trial
China 104161733   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Dow
Moodys
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.